CDK1/2/5 blockade: killing two birds with one stone

Pancreatic ductal adenocarcinoma (PDAC) is an immune resistant tumor. We recently demonstrated that inhibiting CDK1/2/5 by dinaciclib not only blocks immune checkpoint expression, but also triggers histone-dependent immunogenic cell death. This dual mechanism turns immunologically “cold” tumor micro...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jiao, Kang, Rui, Tang, Daolin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Author View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833763/
https://www.ncbi.nlm.nih.gov/pubmed/33537177
http://dx.doi.org/10.1080/2162402X.2021.1875612
Descripción
Sumario:Pancreatic ductal adenocarcinoma (PDAC) is an immune resistant tumor. We recently demonstrated that inhibiting CDK1/2/5 by dinaciclib not only blocks immune checkpoint expression, but also triggers histone-dependent immunogenic cell death. This dual mechanism turns immunologically “cold” tumor microenvironment into a “hot” one, improves overall survival rates in mouse PDAC models.

Ejemplares similares